In the BioHarmony Drug Report Database
Alprostadil
Caverject, Caverject Impulse, Edex, Muse, Prostin Vr Pediatric (alprostadil) is a small molecule pharmaceutical. Alprostadil was first approved as Caverject on 1982-01-01. It is used to treat aortic arch syndromes, aortic coarctation, hypoplastic left heart syndrome, patent ductus arteriosus, and pulmonary hypertension amongst others in the USA. The pharmaceutical is active against prostaglandin E2 receptor EP1 subtype and prostaglandin E2 receptor EP2 subtype. In addition, it is known to target Prostaglandin E2 receptor EP3 subtype, prostaglandin E2 receptor EP4 subtype, cation channel sperm-associated protein 1, prostacyclin receptor, cation channel sperm-associated protein 3, prostaglandin E2 receptor EP2 subtype, prostaglandin D2 receptor, cation channel sperm-associated protein 4, prostaglandin E2 receptor EP1 subtype, and cation channel sperm-associated protein 2.
Trade Name
|
Caverject, Caverject Impulse, Edex, Muse, Prostin Vr Pediatric |
|---|---|
Common Name
|
alprostadil |
ChEMBL ID
|
CHEMBL495 |
Indication
|
aortic arch syndromes, aortic coarctation, hypoplastic left heart syndrome, patent ductus arteriosus, pulmonary hypertension, pulmonary valve stenosis, tetralogy of fallot, tricuspid atresia, vasculogenic impotence |
Drug Class
|
Vasodilators (undefined group); prostaglandins |
Image (chem structure or protein)